Drugs / ATO-101™
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07260162 | Jan 2027 → Jan 2029 expected | urinary bladder cancer | Institut Cancerologie de l'Ouest | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATO-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07260162 ↗ |
| Route | Other | “administered via intravesical instillation” NCT07260162 ↗ |